We are live on
!
Find out more
Lineage Cell Therapeutics
LCTX
LCTX
58 hedge funds and large institutions have $60.8M invested in Lineage Cell Therapeutics in 2013 Q4 according to their latest regulatory filings, with 10 funds opening new positions, 17 increasing their positions, 11 reducing their positions, and 8 closing their positions.
New
Increased
Maintained
Reduced
Closed
55% more repeat investments, than reductions
Existing positions increased: 17 | Existing positions reduced: 11
25% more first-time investments, than exits
New positions opened: 10 | Existing positions closed: 8
4% more funds holding
Funds holding: 56 → 58 (+2)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
5% less capital invested
Capital invested by funds: $63.8M → $60.8M (-$3.03M)
4.79% less ownership
Funds ownership: 35.98% → 31.19% (-4.8%)
92% less call options, than puts
Call options by funds: $32K | Put options by funds: $407K
Holders
58
Holders Change
+2
Holders Change %
+3.57%
% of All Funds
1.68%
Holding in Top 10
1
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.03%
New
10
Increased
17
Reduced
11
Closed
8
Calls
$32K
Puts
$407K
Net Calls
-$375K
Net Calls Change
+$77K
Top Buyers
| 1 |
BC
Broadwood Capital
New York
|
+$1.12M |
| 2 |
Vanguard Group
Malvern,
Pennsylvania
|
+$771K |
| 3 |
BIT
BlackRock Institutional Trust
San Francisco,
California
|
+$462K |
| 4 |
D.E. Shaw & Co
New York
|
+$292K |
| 5 |
VKH
Virtu KCG Holdings
New York
|
+$265K |
